Dimension Capital
Venture capitalActively deployingSan Francisco · Seed–Late Stage · 14 people tracked
Also known as DIMENSION CAPITAL MANAGEMENT LLC · DIMENSION MANAGEMENT, L.P.
Find your way into Dimension Capital
4,122 people in our graph share verified history with the Dimension Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Dimension positions itself as a multistage, research-oriented investment firm focused on companies operating at the frontiers of science and computing. It emphasizes a research-driven approach, backing ventures that combine advances in the life sciences and computational fields.
Source: firm website, verified Sep 15, 2026.
Team · 14 people
from the firm's website & curated & public directories
Founder mafia
2 people who came through Dimension Capital went on to found or lead other companies.
What they invest in
from 21 of 30 portfolio companiesAI & Machine Learning ×16Biotech ×16Deep Tech ×6Healthtech ×6SaaS ×5Enterprise Software ×4Developer Tools ×3Digital Health ×3
HQs:United States×18Canada×1Germany×1United Kingdom×1
Investments · 30 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 42023 · 12022 · 22021 · 12019 · 22017 · 12016 · 12015 · 217 dated
Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets.
AI & Machine LearningBiotechDeep TechHealthtechBoston, US
Markus Warmuth(M.D., Chief Executive Officer)inSharon Townson(Ph.D., Chief Scientific Officer)inJohn Castle(Ph.D., Chief Data and Information Officer)inFilip Janku(M.D., Ph.D., Chief Medical Officer)inPhil Nickson(Ph.D., J.D., Chief Business and Legal Officer)inMagnus Walter(DPhil, Chief Technology Officer)in
Co-investorsAisling CapitalNew Enterprise Associates (NEA)Versant VenturesHBM PartnersAmzak HealthAvoro Capital Advisors+1 more
San Francisco, US
Todd Huffman(Executive Officer, Director)Megan Klimen(Executive Officer)
BoardJoshua Wolfe(Director)Matt Ocko(Director)inAdam Goulborn(Director)
Board seatAdam Goulburn· per SEC Form D · $14M raise · filed Jul 2016
Co-investorsComet LabsDCVC (Data Collective)Dolby Family VenturesLux CapitalOS Fund
Collaborative scholarly writing tool turned preprint archive, owned by Wiley since 2018.
New York, US
Nathan Jenkins(Executive Officer)Alberto Pepe(Executive Officer, Director)Matteo Cantiello(Director)
BoardDavid Teten(Director)Brian Cohen(Director)
Board seatAdam Goulburn· per SEC Form D · $1.5M raise · filed Jan 2016
Co-investorsFf Venture CapitalNew York Venture PartnersBloomberg BetaLux Capital
Professional drone racing league whose pilots fly identical custom-built FPV drones on 3D courses broadcast worldwide.
New York, US
Nicholas Horbaczewski(Executive Officer, Director)
Board seatAdam Goulburn· per SEC Form D · $50M raise · filed Jun 2019
Co-investorsCerity Partners VenturesChaifetz GroupLux CapitalRSE VenturesCRCM VenturesHearst Ventures
NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology.
AI & Machine LearningBiotechLongevitySouth San Francisco, US
Brian Armstrong(Co-founder, Board of Directors)inBlake Byers(Director)inJacob Kimmel(Director)inMichael Polansky(Executive Officer)
Board seatZavain Dar· per SEC Form D
Co-investorsS32Valor Equity Partners8VCAbstract Venturesage1Beyond Capital+8 more
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)in
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)in
Board seatNan Li· per SEC Form D
Co-investorsActivant CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess FundGreatPoint Ventures+8 more
Pager Health provides a white-label care navigation platform that combines AI with clinicians to help members find, access, and stay engaged with healthcare.
AI & Machine LearningDigital HealthHealthtechNew York, US
Gaspard de Dreuzy(Executive Officer, Director)inPhillip Eytan(Executive Officer, Director)Oscar Salazar(Director)Philip Eytan(Executive Officer, Director, Promoter)Walter Jin(Chairman & CEO)inSandy Clarke(Chief Financial Officer)in
Board seatAdam Goulburn· per SEC Form D · $50M raise · filed Jun 2021
Co-investorsHealth Catalyst CapitalNew Enterprise Associates (NEA)Streamlined VenturesGoodwater CapitalLux CapitalMontage Ventures
Riskgaming creates immersive strategy simulation games where high-level decision-makers assume roles and navigate complex scenarios involving technology, business, and geopolitical challenges to explore alternative outcomes and inform real-world decisions.
BiotechHayward, US
Kegan Schouwenburg(Executive Officer, Director)Roger M. Perlmutter(Executive Officer, Director)in
BoardJoshua Wolfe(Director)inDror Berman(Director)James Tananbaum(Director)Leon Chen(Director)
Board seatAdam Goulburn· per SEC Form D · $525M raise · filed Jan 2022
Co-investorsBain Capital Life SciencesCisco InvestmentsForesite CapitalLux Capital
San Francisco, US
Shashank Samala(Cofounder)Jeffrey McAlvay(Executive Officer, Director)Jesse Koenig(Executive Officer)
Board seatZavain Dar· per SEC Form D · $20.7M raise · filed Aug 2017
Co-investorsGrit VenturesKeiretsu ForumLux CapitalPoint72 VenturesSQN Venture Partners, LLCUncork Capital+2 more
Variant Bio is a therapeutics company that uses human genomics to guide drug development, drawing on expertise across genetics, molecular biology, therapeutics, anthropology, and ethics.
AI & Machine LearningBiotechDigital HealthNew York, US
Kaja Wasik(Executive Officer, Director)inAndrew Farnum(Chief Executive Officer)inStephane Castel(Co-Founder, Chief Scientific & Technology Officer)inCraig Basson(Chief Medical Officer, President of R&D)inHolly Vance(Chief Operating Officer)in
BoardJulie Sunderland(Director)
Board seatAdam Goulburn· per SEC Form D · $31.5M raise · filed Oct 2019
Co-investorsAlta PartnersGeneral CatalystLux CapitalSoftBank Vision Fund
.png)
Achira builds molecular world models that blend geometric deep learning, physics, and quantum chemistry to advance drug discovery and materials design.
AI & Machine LearningBiotechDeep Tech
John Chodera(President / CEO)inTheofanis Karaletsos
BoardZavain Dar(Board)in
Co-investorsCompoundNVIDIAAmplify PartnersDIMENSIONNVentures
AllStripes was a health technology company that built a research platform for rare diseases, collecting and de-identifying patients' medical records to power rare disease research.
Digital HealthHealthtech
Nancy Yu(Founder)in
Co-investorsGaruda VenturesJAZZ Venture PartnersLux CapitalMaveronShasta VenturesSpark Capital
Aspect Biosystems develops bioprinted tissue therapeutics using a platform that combines AI-powered bioprinting, computational design tools, therapeutic cells, and biomaterials to create implantable allogeneic tissues.
AI & Machine LearningBiotechLongevity
Tamer Mohamed(Founder & CEO)inSam Wadsworth(Co-founder & Chief Scientific Officer)inSimon Beyer(Co-founder & Chief Technology Officer)inLeela Paris(Chief Technical Operations Officer)inMike Scott(Chief Development Officer)inRay Smith(Chief Financial Officer)in
Co-investorsAngel ForumCivilization Ventures Management, LlcInBC Investment Corp.JDRF T1D FundPage One VenturesPallasite Ventures+5 more
Automata provides lab automation and data management tools, enabling researchers and technicians to generate accurate data at scale through intuitive workflow creation.
Advanced ManufacturingAI & Machine LearningDeep TechHardwareHealthtechLegalTechRoboticsSaaSLondon, GB
Mostafa ElSayed(CEO and Co-Founder)inSuryansh Chandra(Co-Founder)
Co-investorsAir Street CapitalBlue Wire CapitalEntrepreneur FirstHCVCHummingbird VenturesIn-Q-Tel+9 more
Axi.om uses agentic intelligence and AI to predict, explain, and fix drug toxicity early in development by leveraging the largest experimental-to-clinical dataset of profiled molecules linked to human clinical outcomes.
AI & Machine LearningBiotechMedical Devices
Co-investorsAbstract VenturesAmplify PartnersCRV (Charles River Ventures)Inception Studio CapitalAtria Ventures
Chai Discovery builds a computer-aided design suite using artificial intelligence to design new molecules and drugs.
AI & Machine LearningBiotechDeep TechSan Francisco, US
Joshua Meier(Founder & CEO)inJack Dent(Founder)in
Co-investorsAmplify PartnersAvenir Growth CapitalBain Capital VenturesBattery VenturesDCVC (Data Collective)General Catalyst+13 more
Convoke offers an AI platform that ingests and structures data from documents, scientific literature, SEC filings, and clinical data, and deploys custom agents to automate knowledge tasks and generate reports, manuscripts, and landscape analyses.
AI & Machine LearningBiotechEnterprise SoftwareHealthtechSaaS
Co-investorsAudaciousKleiner Perkins6 Dimensions CapitalACMEComma CapitalLux Capital+2 more
Clinical-stage biotech using AI and metabolomics to decode natural chemistry and discover small-molecule medicines.
Viswa Colluru, PhD(Founder)in
Co-investorsAir Street CapitalBoulder VenturesCatalio Capital Management, LPFPVHummingbird VenturesJAZZ Venture Partners+7 more
Fiveonefour builds tooling focused on agent experience (AX), helping developers ship software that AI agents can use effectively.
AI & Machine LearningDeveloper ToolsSaaSPortland, US
Timote Gelinas Delisle(Executive Officer, Director, Promoter)Chris Crane(Founder)inNicolas Joseph(Founder)in
Co-investorsFlybridge Capital PartnersVermilion Cliffs Ventures6 Dimensions CapitalRidge VenturesStage 2 Capital
Kaleidoscope provides a software platform for scientific R&D teams to track and communicate project data, manage complex research processes, and accelerate decision-making.
BiotechEnterprise SoftwareSaaSNew York City, US
Ewan Taylor(CSO and Co-founder)Geraldine Paulus(Co-founder, VP Operations)Brian Naughton(Co-founder and CTO)inDavid Yen(Founder)inBogdan Knezevic(Founder)in
Co-investorsAIN VenturesBurda Principal InvestmentsHAWKTAILHummingbird Ventures3x5 PartnersRally Ventures Management, Llc
Kimia is a therapeutics company developing new drugs through its ATLAS platform, working with partners in the pharmaceutical and biotechnology industries.
AI & Machine LearningBiotechDeep Tech
Stig Hansen(Founder)in
Co-investorsHorizons VenturesThe Column GroupAirTree VenturesBlackbird VenturesDIMENSIONSkip Capital
Lamin provides a lineage-native lakehouse platform for biological R&D that enables scientists to query, trace, and validate complex biological datasets across academia, biotech, and pharma.
AI & Machine LearningBiotechData & InfrastructureDeveloper ToolsEnterprise SoftwareHealthtechMunich, DE
Alex Wolf(Co-Founder & CEO)inSunny Sun(Founder)inFrederic Enard(Co-CTO & Founding Engineer)in
Co-investorsY Combinator
Modal provides a cloud platform that lets developers define compute, hardware, and application logic in Python and deploy to the cloud, with fast-booting containers and autoscaling GPUs.
AI & Machine LearningCloud ComputingDeveloper ToolsNew York, US
Erik Bernhardsson(Founder)inAkshat Bubna(Founder)in
Co-investorsAmplify PartnersLux CapitalRedpoint VenturesCreandumGeneral CatalystAbstraction Capital+9 more
Stately Bio develops stem cell-derived regenerative and cell therapies using a machine learning platform that measures cell identity, behavior, and maturation directly from live-cell, label-free imaging.
AI & Machine LearningBiotechMedical Devices
Frank Li(Founder & CEO)Christian Elabd, PhD(Head of Biology)
Co-investorsAIX VenturesFoothill VenturesMitsui Global InvestmentAxial VCBoxOne VenturesCaffeinated Capital+1 more
Tamarind provides a computational platform for protein and molecular engineering, offering AI and physics-based tools to design antibodies, peptides, enzymes, and small molecules.
AI & Machine LearningBiotechDeep TechEnterprise SoftwareSaaSSan Francisco, US
Deniz Kavi(Co-founder & CEO)inSherry Liu(Founder)in
Co-investorsTreeo VCY Combinator468 Capital6 Dimensions Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CareGuardianEnveda Therapeutics, Inc.Hometeam Technologies, Inc.Congruence TherapeuticsEarendil Labs
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 5
1 IPOs · 4 acquisitions · showing 2Monte Rosa TherapeuticsNASDAQ: GLUEAllStripesacq. by PicnicHealth
Portfolio news
latest coverage across their companies
Enveda · biospace.com · Aug 19, 2026
Riskgaming · gurufocus.com · Aug 12, 2026
Odyssey Therapeutics · finance.yahoo.com · Aug 11, 2026
Tempo Automation · themarketsdaily.com · Aug 10, 2026
Chai Discovery · thenextweb.com · Jul 15, 2026
Axiom Bio · axi.com · Jul 6, 2026
Automata · aol.com · Jun 25, 2026
Public market activity · per SEC filings
what is this? ⓘ2 insider ownership filings (Forms 3/4/5)
at Odyssey Therapeutics, Inc. (ODTX)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Dimension Capital made?
- Dimension Capital has 30 tracked investments, 5 of which have exited, including 7 dated in the last 24 months.
- What stage does Dimension Capital invest at?
- Dimension Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Dimension Capital's typical check size?
- Dimension Capital typically writes checks of $1M – $10M.
- What sectors does Dimension Capital focus on?
- Dimension Capital focuses on AI & Machine Learning, Biotech, Deep Tech, Healthtech, Medical Devices, SaaS.
- Where is Dimension Capital located?
- Dimension Capital is headquartered in San Francisco, US.
- Does Dimension Capital lead rounds?
- Yes, Dimension Capital leads investment rounds.
Media · Podcasts & interviews
featuring the teamVentures #18 w/ Zavain Dar & Nan Li - Co-Founders & Managing Partners @ Dimension Capital | BIOS
BIOS · Nan Li
Images
Co-investors · 48
Lux Capital is a venture capital firm that backs founders building transformative deep technologies, having been among the first investors in category-defining companies across AI, robotics, biotech, defense, and infrastructure.
6 Dimensions Capital is a healthcare-focused investment firm with offices in Boston, San Francisco, Hong Kong, and Shanghai. It backs healthcare startups and growth-stage companies operating in the U.S., Europe, China, Israel, and other markets, with an emphasis on life sciences businesses spanning China and the United States.
Amplify Partners is a venture capital firm that backs technical founders — engineers, researchers, and scientists — building companies across AI/ML, data infrastructure, developer tools, and life sciences.
General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Menlo Ventures is a venture capital firm that invests in transformative, early-stage AI companies across every layer of the modern AI stack, from applications and middleware to data infrastructure and foundation models.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Uncork Capital (formerly SoftTech VC) is a seed-stage venture firm that invests early in founders, with a focus on AI-native companies building leverage and scale.
Spark Capital is a venture capital firm that partners with founders, known for early investments including leading Twitter's Series B in 2008.
True Ventures is a venture capital firm established in 2005 that focuses on early-stage technology companies, with operations based in Silicon Valley.
▶36 more co-investors
Streamlined VenturesMaveronPoint72 VenturesThe Column GroupPage One VenturesCompoundFPVKinnevikAmplitude Venture CapitalAndreessen HorowitzFelicis VenturesFoundation CapitalUnion Square Ventures (USV)Susa VenturesInnovation EndeavorsStellar CapitalAdditionTrajectory Ventures01 Advisors2048 VenturesFootworkBrainchild HoldingsPelion Venture PartnersDigital Currency GroupOyster VenturesHOF CapitalCrunchFundLombardstreet VenturesEuclid Venture PartnersBuilders VCPivotal Life SciencesAnkona CapitalBerkeley Blockchain XceleratorCatalio Capital ManagementInterlagosAvant Bio
Firms observed investing alongside Dimension Capital, from public investor directories. Shared companies are the overlap with Dimension Capital's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.